Theme03:Neurodegenerative disease

We are eager to develop innovative drugs as quickly as possible to bring relief to patients suffering from neurodegenerative diseases around the world!

We wish to collaborate with many partners bringing creative ideas and technologies.

Laboratory for Pharmacology

Answers for a meaningful life.


“ Neurodegenerative disease ”

Recruitment theme 

Neurodegenerative disease

3-1. Novel drug target molecules, drug candidates and therapeutic concepts for neurodegenerative diseases

3-1-1. Polyglutamine Disease, such as spinocerebellar degeneration

Research interests:

  • Prevention of polyglutamine protein aggregation and/or degradation of aggregated polyglutamine protein

Other conditions:

  • in vitro experimental results demonstrating the expected mechanism of action must be already obtained.

3-1-2. Synucleinopathy, such as Multiple System Atrophy (MSA)

Research interests:

  • Prevention of α-synuclein aggregation and/or degradation of aggregated α-synuclein aggregation

Other conditions:

  • in vitro experimental results demonstrating the expected mechanism of action must be already obtained..

3-1-3. Tauopathy, such as Progressive Supranuclear Palsy (PSP)

Research interests:

  • Prevention of Tau aggregation and/or degradation of aggregated Tau

Other conditions:

  • in vitro experimental results demonstrating the expected mechanism of action must be already obtained.

3-1-4. TDP-43 Proteinopathy, such as sporadic Amyotrophic Lateral Sclerosis (sALS)

Research interests:

  • Prevention of TDP-43 aggregation and/or degradation of aggregated TDP-43

Other conditions:

  • in vitro experimental results demonstrating the expected mechanism of action must be already obtained.
3-2. Drug development technologies for neurodegenerative diseases

3-2-1. Animal models that can evaluate drug efficacy for Multiple System Atrophy (MSA)

Research interests:

  • Animal models with α-synuclein aggregation

Other conditions:

  • Experimental results suggesting motor dysfunction must be already obtained.

3-2-2. Assay systems using patient-derived induced pluripotent stem cells (iPSCs) that can evaluate drug efficacy for neurodegenerative diseases

Research interests:

  • Evaluation of drug efficacy for Polyglutamine Diseases, Synucleinopathy, Tauopathy and TDP-43 Proteinopathy

Other conditions:

  • Experimental results demonstrating intracellular protein aggregation must be already obtained.

Subscription 

Click “Apply” to proceed to the application form.

pagetopボタン